A Danish pharmaceutical company announced Thursday that its investigational migraine medication demonstrated effectiveness in reducing monthly headache episodes during a mid-stage clinical trial.
The company, Lundbeck, reported that bocunebart showed promise as a treatment for migraines, which rank among the most prevalent neurological conditions worldwide. The experimental medication works by targeting the PACAP pathway associated with migraines, which differs from the CGRP pathway addressed by some current preventive medications. This distinction could provide a treatment alternative for individuals who don’t respond effectively to existing therapies.
During the intravenous portion of the clinical study, bocunebart achieved its main objective among participants who had experienced one to four unsuccessful previous preventive treatments. The medication decreased monthly migraine episodes by an average of 4.24 days during weeks one through 12, compared to 2.86 days for participants receiving placebo treatment.
According to Lundbeck’s presentation at the American Headache Society congress in Orlando, Florida, this represents a placebo-adjusted decrease of 1.38 days.
Financial analysts from Jefferies had anticipated that multiple intravenous treatments would demonstrate a “modest step up” from an earlier study, where a single administration reduced monthly migraine days by two on a placebo-adjusted basis over a four-week period.
When examining combined data from mid-stage studies involving patients with severe, chronic migraines, Lundbeck reported an enhanced effect. In this population, bocunebart decreased monthly migraine days by 2.31 more days compared to placebo treatment.
The experimental drug showed good tolerability overall, with researchers reporting no new safety concerns. The most frequently observed treatment-related side effect, occurring in at least 5% of study participants, was nasopharyngitis, which causes cold-like symptoms.
Jefferies analysts project the medication could achieve peak worldwide sales of $400 million.
